Multi-Omics Biomarker Discovery: Methods, Evidence, and Applications
Biomarker discovery has a measurement problem. Most studies look at one molecular layer at a time — proteins, or metabolites, or lipids — and integrate the results afterward, across different labs and platforms. But disease biology doesn't respect those boundaries. The signals that actually distinguish a condition often live in the coordination between layers: a metabolite shift that only makes sense alongside a protein change. Multi-omics biomarker discovery measures those layers together, from the same sample, so coordinated signatures are preserved instead of lost.
What is multi-omics biomarker discovery?
A biomarker is a measurable molecule that indicates a biological state — disease risk, progression, or treatment response. "Multi-omics" means measuring several molecular classes at once: the proteome, metabolome, lipidome, and sometimes the transcriptome. Combining these layers finds signatures single-omics approaches miss. This is the core of our multi-omics services: profiling proteins, metabolites, lipids, electrolytes, and more from a single sample.
Why single-sample, single-run matters
The traditional approach splits a sample across platforms or labs and stitches results together later, introducing batch effects and cross-platform variability. Both can swamp the biological signal — especially in small cohorts, where technical artifacts masquerade as real differences. Measuring all layers in one run, on one sample, removes that noise. Our Omni-MS platform uses a single LC-MS assay to profile proteins, lipids,metabolites, electrolytes, and drugs together, preserving data integrity across layers.
The molecular layers — and what each reveals
- Proteomics: proteins are the workhorses of biology; changes reveal active signaling, inflammation, and structural remodeling.
- Metabolomics: the downstream readout of metabolism, shifting fast to reflect real-time physiology.
- Lipidomics: lipids drive membrane biology, signaling, and energy storage; central to metabolic and inflammatory disease.
- Transcriptomics: RNA shows which genes are actively expressed, adding regulatory context.
The power comes from reading them together: a lipid change plus a complement-protein change plus a metabolite shift can point to one coherent mechanism.
What coordinated signals look like — evidence
A concrete example from our own work: in a study of 22q11.2 deletion syndrome, we profiled plasma metabolites and proteins from the same samples. Neither layer alone told the full story — but together, lowered metabolites (taurine, arachidonic acid) lined up with changes in complement-cascade proteins (C3, C4B, SERPINA1, SERPING1), converging on a single inflammatory and lipid-signaling axis. That convergence is the signature. Read the full research spotlight. Similar coordinated signatures appeared in our work on severe COVID-19 in pregnancy, where complement activation and serum-lipid dysregulation emerged together
From discovery to validation
Finding candidate biomarkers is the start; validating them is the work — rigorous statistics, attention to cohort size and confounders, reproducibility across batches, and turning a signature into a defined, measurable panel. Our data analysis services cover quality control, batch correction, statistical modeling, and visualization so candidate signatures hold up and can serve as outcome measures in trials.
Applications
- Drug development: characterizing the full molecular effect of an intervention; finding pharmacodynamic and safety biomarkers.
- Clinical biomarkers: non-invasive blood-based signatures for diagnosis, risk stratification, and monitoring.
- Bioprocessing: understanding biochemical factors that drive cell growth and product yield.
See our applications and analytical services for drug development and biomarker discovery
Frequently asked questions
- What sample types can be analyzed? Plasma and serum are most common, but the platform handles many biological matrices.
- How many samples do I need? Multiomics can surface strong leads even in small cohorts when layers agree, though larger validation is recommended.
- Proteomics vs. metabolomics — which should I use? For biomarker discovery you usually don't choose: measuring both (plus lipids) gives the coordinated signal single layers miss.
Further reading
Explore the peer-reviewed research authored by our scientists, and studies powered by our platform, on our Publications page